{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:14:11Z","timestamp":1786432451534,"version":"build-2736575974"},"reference-count":30,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15178","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:38:18Z","timestamp":1751877498000},"page":"1-8","source":"Crossref","is-referenced-by-count":1,"title":["Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review"],"prefix":"10.3892","volume":"30","author":[{"given":"Xirui","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu 211800, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"key20250812093625_b1-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"key20250812093625_b2-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","article-title":"Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients","volume":"114","author":"Tian","year":"2017","journal-title":"Lung Cancer"},{"key":"key20250812093625_b3-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"key20250812093625_b4-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12916-021-02207-x","article-title":"Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study","volume":"20","author":"Zou","year":"2022","journal-title":"BMC Med"},{"key":"key20250812093625_b5-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.21037\/tlcr-21-160","article-title":"Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib","volume":"10","author":"Li","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"key20250812093625_b6-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.3390\/curroncol29100530","article-title":"STRN-ALK fusion in lung adenocarcinoma with brain metastasis responded well to ensartinib: A case report","volume":"29","author":"Zhang","year":"2022","journal-title":"Curr Oncol"},{"key":"key20250812093625_b7-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jtho.2016.01.024","article-title":"The IASLC lung cancer staging project: Methodology and validation used in the development of proposals for revision of the stage classification of NSCLC in the forthcoming (eighth) edition of the TNM classification of lung cancer","volume":"11","author":"Detterbeck","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20250812093625_b8-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov"},{"key":"key20250812093625_b9-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small cell lung cancer: Results of an open-label, multicenter, phase 1b study","volume":"15","author":"Felip","year":"2020","journal-title":"J Thorac Oncol"},{"key":"key20250812093625_b10-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/embor.2009.94","article-title":"TIP150 interacts with and targets MCAK at the microtubule plus ends","volume":"10","author":"Jiang","year":"2009","journal-title":"EMBO Rep"},{"key":"key20250812093625_b11-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13073-015-0228-1","article-title":"A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients","volume":"7","author":"Pongor","year":"2015","journal-title":"Genome Med"},{"key":"key20250812093625_b12-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1002\/alz.13718","article-title":"Whole genome-wide sequence analysis of long-lived families (long-life family study) identifies MTUS2 gene associated with late-onset Alzheimer's disease","volume":"20","author":"Xicota","year":"2024","journal-title":"Alzheimers Dement"},{"key":"key20250812093625_b13-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"646","DOI":"10.21037\/tlcr-19-403","article-title":"The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"key20250812093625_b14-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-22-3413","article-title":"Clinicopathologic, genomic, and immunophenotypic landscape of ATM mutations in non-small cell lung cancer","volume":"29","author":"Ricciuti","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20250812093625_b15-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"6734","DOI":"10.3390\/ijms25126734","article-title":"Antineoplastic effect of ALK inhibitor crizotinib in primary human anaplastic thyroid cancer cells with STRN-ALK fusion in vitro","volume":"25","author":"Ferrari","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20250812093625_b16-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"11954","DOI":"10.3390\/ijms252211954","article-title":"The impact of genetic mutations on the efficacy of immunotherapies in lung cancer","volume":"25","author":"Lui","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20250812093625_b17-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/j.cllc.2018.11.002","article-title":"Identification and development of a lung adenocarcinoma PDX model with STRN-ALK fusion","volume":"20","author":"Ren","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"key20250812093625_b18-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"9476","DOI":"10.1111\/jcmm.16897","article-title":"Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review","volume":"25","author":"Li","year":"2021","journal-title":"J Cell Mol Med"},{"key":"key20250812093625_b19-ol-30-3-15178","first-page":"100125","article-title":"STRN-ALK, A novel in-frame fusion with response to alectinib","volume":"2","author":"Nagasaka","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"key20250812093625_b20-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1016\/j.jtho.2017.08.009","article-title":"Case report of non-small cell lung cancer with STRN-ALK translocation: A nonresponder to alectinib","volume":"12","author":"Nakanishi","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20250812093625_b21-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1235679","DOI":"10.3389\/fonc.2023.1235679","article-title":"Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib","volume":"13","author":"Song","year":"2023","journal-title":"Front Oncol"},{"key":"key20250812093625_b22-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"12515","DOI":"10.2147\/OTT.S282933","article-title":"STRN-ALK fusion in lung adenocarcinoma with excellent response upon alectinib treatment: A case report and literature review","volume":"13","author":"Su","year":"2020","journal-title":"Onco Targets Ther"},{"key":"key20250812093625_b23-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/1759-7714.13983","article-title":"Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report","volume":"12","author":"Sun","year":"2021","journal-title":"Thorac Cancer"},{"key":"key20250812093625_b24-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mayocpiqo.2017.04.003","article-title":"A rare STRN-ALK fusion in lung adenocarcinoma identified using next-generation sequencing-based circulating tumor DNA profiling exhibits excellent response to crizotinib","volume":"1","author":"Yang","year":"2017","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"key20250812093625_b25-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"722843","DOI":"10.3389\/fonc.2021.722843","article-title":"Case report: Identification of two rare fusions, PDK1-ALK and STRN-ALK, that coexist in a lung adenocarcinoma patient and the response to alectinib","volume":"11","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"key":"key20250812093625_b26-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/CAD.0000000000001094","article-title":"Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: A case report","volume":"32","author":"Zeng","year":"2021","journal-title":"Anticancer Drugs"},{"key":"key20250812093625_b27-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.jtho.2019.02.014","article-title":"Responder of gefitinib plus crizotinib in osimertinib failure EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by next-generation sequencing","volume":"14","author":"Zhou","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key20250812093625_b28-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"key20250812093625_b29-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): A randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"key20250812093625_b30-ol-30-3-15178","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ijc.34123","article-title":"Special issue \u2018The advance of solid tumor research in China\u2019: Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China","volume":"152","author":"Su","year":"2023","journal-title":"Int J Cancer"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T06:36:33Z","timestamp":1754980593000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15178","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}